REG - ReNeuron Group plc - Block Listing Review and Total Voting Rights

ReNeuronAnnouncement

02/03/2020 07:00

RNS Number : 5913E
  
ReNeuron Group plc
  
02 March 2020
  
 

 



2 March 2020


AIM: RENE



 
ReNeuron Group plc
("ReNeuron" or the "Company")
 
Block Listing Review and Total Voting Rights
 
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, provides the following update in accordance with Schedule Six of the AIM Rules for Companies regarding its existing block listing arrangements.
 



Name:


ReNeuron Group plc




Name of Scheme:


ReNeuron Share Option Schemes




Period of Return:


From 1 September 2019 to 29 February 2020




Balance of unallotted securities under scheme(s) from previous return:


716,741 Ordinary Shares (of 1p each)
 




Plus: The amount by which the block scheme(s) has been increased since the date of the last Review (if any increase has been applied for):


N/A




Less: Number of securities issued/allotted under scheme(s) during period


 
1,500




Equals: Balance under scheme(s) not yet issued/allotted at end of period:


715,241 Ordinary Shares




Number and class of securities originally admitted and the date of admission:


20,000 ordinary shares on 13 May 2010



 
 
Total Voting Rights
At 29 February 2020, the Company had 31,833,770 Ordinary Shares in issue, all with voting rights. The Company holds no Ordinary Shares in treasury.  The figure of 31,833,770 Ordinary Shares may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the Company under the FCA's Disclosure and Transparency Rules.
 
ENDS
 
ENQUIRIES:
 



Contacts:
 
ReNeuron


 
 
+44 (0) 20 3819 8400




Olav Hellebø, Chief Executive Officer




Michael Hunt, Chief Financial Officer




 
Buchanan (UK Media/Investor Relations)


 
+44 (0) 20 7466 5000




Mark Court, Tilly Abraham




 
Argot Partners (US Media/Investor Relations)
Claudia Styslinger, David Rosen


 
+1 212 600 1902




 


 




Stifel Nicolaus Europe Limited (NOMAD and Joint Broker)
Jonathan Senior, Stewart Wallace, Ben Maddison


+44 (0) 20 7710 7600
 




 
N+1 Singer (Joint Broker)
Aubrey Powell, James Moat, Tom Salvesen


 
+44 (0) 20 7496 3000




 


 



 
About ReNeuron
ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs.  The Company's lead clinical-stage candidates are in development for the blindness-causing disease, retinitis pigmentosa, and for disability as a result of stroke.  ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that would otherwise be unable to reach their site of action.  ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.  For further information visit www.reneuron.com. 
 
 
 
 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
MSCKKDBDCBKDONK